From the Editors

It was on the front page of my newspaper. It is in the data services I subscribe to for the American Society of Health-System Pharmacists and the American Society of Clinical Oncology. It is the feature of a new survey from the Hematology Oncology Pharmacy Association and is the lead-in for the Pharmacists’ Newsletter. It is on the nightly news, and it was explored in depth in the last issue of the Journal of Hematology Oncology Pharmacy (JHOP).

It was on the front page of my newspaper. It is in the data services I subscribe to for the American Society of Health-System Pharmacists and the American Society of Clinical Oncology. It is the feature of a new survey from the Hematology Oncology Pharmacy Association and is the lead-in for the Pharmacists’ Newsletter. It is on the nightly news, and it was explored in depth in the last issue of the Journal of Hematology Oncology Pharmacy (JHOP).

In this month’s issue of The Oncology Pharmacist (TOP), we explore the growth of specialty pharmacies and the implications for our relationship with patients. Author Lea Ann Hansen discusses the evolution of specialty pharmacy and the function it serves in the treatment of cancer and how this affects patients. As Hansen points out in her article, “In many cases, the complicated nature of administration or possible adverse events with specialty drugs necessitate intensive patient monitoring.”

In this month’s issue of The Oncology Pharmacist (TOP), we continue our coverage of the news from the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) by addressing the topic of chemotherapy dosing for patients who are obese.
In this month’s issue of The Oncology Nurse-APN/PA (TON), we bring you the news from the European Society for Medical Oncology 2012 Con­gress. Some of the most exciting news came from the update of the PROFILE 1007 trial, with results showing that crizotinib was more effective than standard chemo­therapy with pemetrexed or doce­taxel as a second-line treatment for non–small cell lung cancer. We also cover the latest treatment information about pancreatic neuroendocrine tumors, which, as one presenter noted, is “not a rare disease any longer.”
October is National Breast Cancer Awareness Month. The October 1, 2012, presidential proclamation acknowledging this points out that “Breast cancer touches the lives of Americans from every background and in every community across our Nation.”
In this month’s issue of The Oncology Pharmacist (TOP), we wrap up the year with highlights of the news from the 2012 American Society for Radiation Oncology Annual Meeting and the European Society for Medical Oncology 2012 Congress.
This issue of The Oncology Nurse-APN/PA (TON) brings you highlights of the news from the 2012 American Society for Radiation Oncology (ASTRO) annual meeting. Part of our ASTRO coverage includes the results of a study that show that many patients with incurable lung cancer misunderstood the goals of palliative radiation therapy.
Welcome to the first issue of The Oncology Nurse-APN/PA (TON) for 2013. We’ll be publishing 11 issues this year, keeping you up-to-date about what is happening in the world of oncology research and bringing you information that helps you in your day-to-day practice.
With this issue of The Oncology Nurse-APN/PA (TON), we continue our coverage of the news from the 54th Annual Meeting of the American Society of Hematology (ASH) and the San Antonio Breast Cancer Symposium (SABCS).
Page 1 of 7
Results 1 - 10 of 65